Zogenix competitors

Zogenix Competitors include Intarcia Therapeutics, Recro Pharma, BTG and Antidote.
Add company...
Zogenix
Zogenix
Specialty pharmaceutical developing CNS and pain therapies and featuring DosePro needle free delivery technology.
Intarcia Therapeutics
Intarcia Therapeutics
Intarcia Therapeutics is a biopharmaceutical company developing innovative therapies for chronic diseases.
Recro Pharma
Recro Pharma
Recro Pharma is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post operative pain.
BTG
BTG
BTG is an international specialist healthcare company.
Antidote
Antidote
Antidote is accelerating the breakthroughs of new treatments by bridging the gap between medical research and the people who need them.
Founding Date
Founding Date
2006
Founding Date
1997
Founding Date
2006
Founding Date
1948
Founding Date
2009
Type
Type
Public
Type
Private
Type
Public
Type
Subsidiary
Type
Private
Tags
Locations
Locations
Emeryville, US HQ
Windsor And Maidenhead, GB
Locations
Boston, US HQ
Durham, US
Hayward, US
Locations
Malvern, US HQ
Locations
London, GB HQ
Rosedale, AU
Ottawa, CA
Düsseldorf, DE
Hong Kong , HK
Ataşehir, TR
Ffostrasol, GB
see more
Locations
London, GB HQ
New York, US
Carmel, US
Employees
Employees
9032% increase
Employees
3142% increase
Employees
195
Employees
N/A
Employees
52
Valuation ($)
Valuation ($)
1.6 b
Valuation ($)
3.9 b
Valuation ($)
199 m
Valuation ($)
N/A
Valuation ($)
N/A
Twitter followers
Twitter followers
499
Twitter followers
500
Twitter followers
N/A
Twitter followers
1 k
Twitter followers
1

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$77.3m (FY, 2018)
Revenue (est.)
£620.5m (FY, 2018)
Revenue (est.)
£2.2m (FY, 2017)
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$43.2m (FY, 2018)
Cost of goods
£185.9m (FY, 2018)
Cost of goods
£892.3k (FY, 2017)
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
$34.2m (FY, 2018)
Gross profit
£434.6m (FY, 2018)
Gross profit
£1.3m (FY, 2017)
Net income
Net income
($123.9m) (FY, 2018)
Net income
N/A
Net income
($79.7m) (FY, 2018)
Net income
£12.7m (FY, 2018)
Net income
(£4.6m) (FY, 2017)

Funding

Latest funding round
Latest funding round
N/A
Latest funding round
$ 215m (over 2 years ago)
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
$ 13.5m (over 4 years ago)
Total funding raised
Total funding raised
N/A
Total funding raised
$ 1.9b
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 17.9m
For sources of this data, please see the company profileDownload Excel

View company profiles

Intarcia Therapeutics
HQ
Boston, US
Employees
314↑ 2% increase

Intarcia Therapeutics is a biopharmaceutical company developing innovative therapies for chronic diseases.

View company
Recro Pharma
HQ
Malvern, US
Employees
195

Recro Pharma is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post operative pain.

View company
BTG
HQ
London, GB

BTG is an international specialist healthcare company.

View company
Antidote
HQ
London, GB
Employees
52

Antidote is accelerating the breakthroughs of new treatments by bridging the gap between medical research and the people who need them.

View company